PORT WASHINGTON, NY–(Marketwire – December 7, 2010) – iiBIG returns to America’s Healthcare Silicon Valley to present the industry-leading Investment and M&A Opportunities in Healthcare, January 25-26, 2011, at the Nashville Convention Center in Nashville, Tennessee. In 2011, experts are predicting an increase in middle-market M&A deal flow in all sectors — however, healthcare will continue to lead all others. Now that financing is becoming easier to find, pent up demand for deals in the middle-markets, and especially in this sector, are expected to increase dramatically. At this conference, attendees will hear from and network with experts and insiders on the status of deal-making in the healthcare sector and how and where deals are getting done.

Executive Speaking Faculty Includes: Alvarez & Marsal; Bass, Berry & Sims PLC; Belmont Village Senior Living; Benesch, Friedlander, Coplan & Aronoff LLP; Bertram Capital Management LLC; Capella Health; Coker Capital Advisors; CredenceHealth; Cressey & Company LP; Diatherix Laboratories, Inc.; DOHI; Epsilon Securities, LLC; EpsteinBeckerGreen; GTCR Golder Rauner, LLC; Healthcare Finance Group, LLC; Healthcare Productivity Automation; IASIS Healthcare Corporation; Iora Health; MedSolutions; Nashville Health Care Council (NHCC); Oak Hill Capital Partners; Penn Medicine; PricewaterhouseCoopers; Raymond James & Associates; Regence Group (Blue Cross/Blue Shield Oregon and Utah); RehabCare Group, Inc.; Renal Advantage, Inc.; Riordan, Lewis & Haden Equity Partners; Sonenshine Partners; SunTrust Robinson Humphrey; Tenet Healthcare; and Vanguard Health Systems.

Conference Sponsors include: Bass, Berry & Sims PLC; EpsteinBeckerGreen (EBG); PricewaterhouseCoopers; SunTrust Robinson Humphrey; Alvarez & Marsal; Benesch; Healthcare Finance Group (HFG); Raymond James & Associates, Inc.; Coker Capital Advisors; Riordan, Lewis & Haden Equity Partners; Sonenshine Partners; and Whyte Hirschboeck Dudek S.C.

Register by December 31, 2010 and Save $200! Healthcare Providers: Register at $595
For more conference information and/or to register: http://www.iibig.com/F1101.

About iiBIG
iiBIG (International Institute for Business Information & Growth) is an unbiased, independent company dedicated to organizing business-to-business conferences and seminars for senior-level business executives. We provide learning and networking settings for some of the business community’s BIGgest thinkers — those who occupy the highest levels in their companies and organizations. Our events focus on the most pressing and timely issues facing decision-makers in today’s global economy. For more information, visit: http://www.iibig.com. 

SAN DIEGO, CA–(Marketwire – December 7, 2010) – Adamis Pharmaceuticals Corporation (OTCBB: ADMP) announced the successful completion of a Phase 3 contraceptive trial of the company’s contraceptive gel product candidate named Savvy® (C31G). The study met its primary endpoint and was conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), in the Contraceptive Clinical Trials Network at 14 sites in the United States. The results of the NICHD study are published in Obstetrics and Gynecology, v.116, pages 1265-1273, in December, 2010.

The Phase 3 trial was a randomized, double-masked, controlled comparator study to assess whether a gel containing the spermicide, C31G, was non-inferior to Conceptrol®, a commercially available product containing nonoxynol-9 (N-9). The clinical investigators found that C31G was not inferior in contraceptive efficacy to the comparator drug Conceptrol®. Thus, the study met its primary objective. Moreover, the gel was well-tolerated and had a high degree of acceptability in women who completed the study. No drug-related serious adverse events were observed with C31G. Drug-related side effects of C31G were generally mild and did not lead to discontinuation.

Currently, all spermicides commercially available in the U.S. contain the active ingredient N-9 in a carrier such as a gel, film, cream, foam, suppository, or tablet. N-9 has been reported in some studies to cause irritant and allergic reactions in some users. Although the Conceptrol® product was effective and well-tolerated in the NICHD comparative trial, there were a significantly lower number of drug-related events with the C31G gel and fewer women discontinued the study due to drug-related side effects. In an interview with Reuters Health, lead researcher Dr. Anne E. Burke of The John’s Hopkins School of Medicine stated, “There are concerns with nonoxynol-9, such as vaginal side effects and genital irritation for some users. It seems that C31G might offer improvements in those regards.” C31G does not contain nonoxynol-9 and, if commercialized, may offer a welcome alternative for women who seek a non-hormonal method of contraception. 

C31G previously was the subject of two Phase 3 clinical trials conducted in Africa, supported by Family Health International and the United States Agency for International Development, to determine whether C31G was safe and effective for reducing women’s risk of acquiring HIV infection. The external independent Data Monitoring Committee reviewing those trials concluded in 2005 and 2006 that, while there were no safety concerns based on the results of the studies to date, continuing the trials would not allow the effect of C31G on HIV acquisition to be determined because of a lower than expected rate of HIV seroconversion in the trials. The committee determined that continuation of the trials was not warranted due to a lack of statistical significance between C31G gel and the vehicle control in the interim data. Accordingly, the trials were discontinued.

Adamis estimates that the market for a product with the characteristics of C31G to be in the $500 million range. Dr. Dennis J. Carlo, President and CEO, stated, that “Since the product does not fit in the core business of the company, Adamis is currently evaluating various out-licensing opportunities. We are currently in discussions with multiple organizations that have a focus or business unit in the area of contraception.”

About Adamis Pharmaceuticals

Adamis Pharmaceuticals has three wholly-owned subsidiaries: Cellegy Holdings, Inc.; Adamis Corporation; and Biosyn, Inc. Adamis Corporation has two wholly-owned subsidiaries, Adamis Laboratories and Adamis Viral Therapies. Adamis Labs has niche prescription products in the allergy and respiratory therapeutic area and intends to launch additional products in this area. Adamis Viral Therapies is focused on the development of patented, proprietary technologies for the potential treatment of human prostate cancer.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations or future financial performance, including, but not limited to the following statements: the company’s ability to successfully develop and market C31G assuming it is approved for marketing by the FDA and other regulatory authorities; regulatory issues or delays with the FDA; and the intellectual property protection that may be afforded by any patents or patent applications relating to C31G. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis’ actual results to be materially different from these forward-looking statements. These risks and uncertainties include, but are not limited to: whether C31G will be approved for marketing by the FDA and other regulatory authorities; whether the company will be able to obtain required funding to pursue activities relating to C31G; whether C31G is a commercially viable product and can be commercialized, manufactured, and marketed in a cost-effective manner; the extent of consumer demand for any such product; and whether any third party will be interested in entering into agreements relating to development and marketing of C31G. It is uncertain whether C31G will ever be commercialized or whether the company will ever realize revenues therefrom. Certain of these risks, uncertainties, and other factors, as well as other risks and uncertainties relating to the company’s business are described in greater detail in Adamis’ filings from time to time with the SEC, all of which are available free of charge on the SEC’s web site at http://www.sec.gov. Adamis expressly disclaims any intent to update any forward-looking statements.

NEW YORK, NY and JERUSALEM–(Marketwire – December 7, 2010) – The International Center for Autism Research and Education (ICare4autism), a New York-based charity, announced plans to create the world’s first Global Autism Center on Mt. Scopus in Israel, dedicated to catalyzing breakthrough innovation in autism research and treatment. In a ceremony at Jerusalem‘s City Hall hosted by Mayor Nir Barkat, ICare4autism’s President Joshua Weinstein signed an agreement paving the way for ICare4autism to acquire the campus of Bezalel Academy of Art in 2013, and convert it into a center, housing:

• State-of-the-art autism research facilities to serve as a platform for global collaboration.

• The world’s first university-level school of autism studies, to raise therapeutic standards worldwide.

• A model school, applying the latest research, technology and design to the needs of students across the Autistic Spectrum.

• A foundation to support transformative global collaborations in autism education and treatment.

Joshua Weinstein said, “To tackle the global autism epidemic, we need a community of researchers, educators and advocates that reaches across borders. Our new Center will give us the ability to convene and empower that community.”

Said Dr. Eric Hollander, Chairman of ICare4autism’s Scientific Advisory Council, “The Center will drive the research needed to discover the etiology of autism, ultimately leading to better methods of detection and treatment.”

Said Mayor Barkat, “We welcome ICare4autism’s plan to create a Global Autism Center on Mt. Scopus, and we look forward to the breakthroughs in research that will emanate from its campus to benefit the entire world.”

About Joshua Weinstein, MBA and MA Ed
Mr. Weinstein is the Founder of ICare4autism, which encompasses Shema Kolainu – Hear our Voices School and Center for Children with Autism in New York City, and Tishma – ABA School and Center for Children with Autism in Jerusalem, Israel.

About Dr. Eric Hollander, MD
Dr. Hollander, Chairman of the Advisory Council of ICare4autism, is a renowned psychiatrist on the faculty of Montefiore Medical Center University Hospital of Albert Einstein College of Medicine, former Chair of Psychiatry at the Mt. Sinai School of Medicine and Director of the Seaver and Greater New York Autism Center of Excellence.

id=”nav_links”>

TUSTIN, CA–(Marketwire – December 7, 2010) –   Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) in partnership with Jaiva Technologies, today announced the formation of NuVax Therapeutics, Inc. (“NuVax”) — a wholly owned subsidiary of Radient Pharmaceuticals. The formation of NuVax Therapeutics is a strategic move on the part of RPC to enhance the Company’s Q2 2010 collaboration agreement with U.S.-based Jaiva Technologies — a biotechnology company focused on the research and development, distribution, marketing and sales of promising third?party healthcare technology products. 

NuVax, a clinical stage pharmaceutical company, aims to develop novel immune-gene therapeutics that have the potential to significantly impact and extend the quality of life for cancer patients. Through the newly formed NuVax Therapeutics, RPC and Jaiva Technologies will utilize RPC’s Combined Immunogene Therapy (“CIT”) cancer therapy to carry out human phase II clinical trials and develop products that will be first in-line therapies for largely unmet medical needs for cancer. The rights to RPC’s CIT technology are anticipated to be transferred to NuVax and 100% of future product development and commercialization, including the development and in-licensing of the up to five additional cancer-fighting technologies will be managed through NuVax under the leadership of Jaiva Technologies Founder, President and CEO Dr. Umesh Bhatia. Dr. Bhatia’s team will be responsible for engagement with clinical laboratories, hospitals and physicians in multiple international locations; conducting clinical trials for CIT technology; securing government approval for the use of CIT as a cancer therapy and vaccine throughout select markets; expansion and management of stage II clinical trials in multiple international locations including the U.S.; and full commercialization of CIT and all other in-licensed therapies in other select international markets. 

In 2001, RPC acquired CIT for approximately US$2 million in cash. The Company has since invested approximately US$1 million in additional capital for patent protection with a U.S. patent issued May 25, 2004. Developed by Dr. Lung-Ji Chang, CIT is a cancer therapy that works by simultaneously incorporating two genes directly into a patient’s tumor cells to enhance their immune system’s natural ability to destroy other cancer cells. CIT targets cancer cells for immunological attack while simultaneously stimulating a stronger immune response against the tumor cells. Dr. Chang currently serves as a consultant to RPC for the continued development of CIT and other gene therapies.

According to RPC Chairman and CEO Mr. Douglas MacLellan, “The formation of NuVax Therapeutics provides a unique platform to significantly accelerate and expand our planned collaboration with Jaiva Technologies, specifically as it relates to the commercialization of CIT, in-licensing new cancer therapies and conducting stage II human clinical trials to ultimately introduce these products to market. Simultaneously, it allows us to dedicate RPC resources to the continued worldwide commercialization of our Onko-Sure In Vitro Diagnostic cancer test. Together we anticipate success through both Companies to drive long-term growth and shareholder value.”

To support the growth and success of NuVax, RPC and Jaiva Technologies have established an internationally renowned executive and scientific team and board of directors that include RPC Chairman and CEO Mr. Douglas Maclellan, RPC COO and Chief Financial Officer Mr. Akio Ariura, Jaiva Technologies Founder, President and CEO Dr. Umesh Bhatia, RPC Board member Mr. Michael Boswell, Dr. Lung-Ji Chang, Professor of Molecular Genetics and Microbiology at the University of Florida Gainesville, and Dr. Afsaneh Motamed-Khorasani, Director of Oncology at RPC.

New to the team is Dr. Donald P. Francis — Dr. Francis worked for CDC from 1971 to 1992: smallpox (assigned to WHO) in India, Bangladesh, Sudan and the former Yugoslavia, cholera in Nigeria, Ebola in Sudan, Assistant Director, Hepatitis Division, Assistant Director, Virology Division. From 1981 he worked on HIV/AIDS: Coordinator of Laboratory Activities (Atlanta), Consultant to State of California (Berkeley) and San Francisco Mayor’s office. His AIDS efforts were chronicled in And the Band Played On, by Randy Shilts. In 1993 he joined Genentech where his HIV vaccine work began. In 1995, Dr. Francis co-founded a spin-off of Genentech called VaxGen where the world’s first efficacy trials were completed in the United States, Canada, Holland and Thailand. In 2004, Dr. Francis retired from VaxGen to establish a not-for-profit foundation, Global Solutions for Infectious Diseases, dedicated to developing vaccines for the less developed parts of the world. In 2009, the first successful HIV vaccine trial was reported. That trial used GSID’s vaccine combined in a “prime-boost format” with one from Sanofi. In addition to HIV, Dr. Francis works with international vaccine manufacturers on vaccines for dengue and influenza. He is a frequent consultant for WHO. Dr. Francis is anticipated to serve as an advisor and member of NuVax’s Board of Directors of NuVax.

After completing undergraduate studies at the University of California at Berkeley, Dr. Francis received his M.D. from Northwestern University and his Doctor of Science in Virology from Harvard. In addition, he completed his pediatric training at the University of Southern California Medical Center in Los Angeles and his infectious disease training at Harvard.

About Jaiva Technologies
Jaiva Technologies is a US?based biotechnology company founded by Dr. Umesh Bhatia that is focused on the research and development, distribution, marketing and sales of promising third?party healthcare technology products, including RPC’s CIT cancer therapy and vaccine.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

ATLANTA, GA–(Marketwire – December 7, 2010) – The Southeastern Medical Device Association’s (SEMDA) 5^th annual conference will take place on March 29-30, 2011, adding a half day to the popular medical device event. Recognized as the premier gathering for the Southeast medical device industry, the conference balances presentations by medical device companies to investors with educational programs and networking opportunities.

Specifically designed to meet the needs of medical device industry professionals, the expanded format will allow additional time for educational and panel presentations, as well as one-on-one meetings.

Another addition for 2011 is a Gala Dinner, which will be held on March 29 at the Georgia Tech Hotel and Conference Center. The annual SpotLight Awards, which recognize individuals and companies that have made substantial contributions to the growth of the Southeastern medical device industry, will be presented during the dinner.

This year’s conference will be held at the Georgia Tech Global Learning Center, a midtown Atlanta conference facility that offers more room for presentations and meetings, complemented by state-of-the-art technology capabilities.

Other highlights will include:

• Keynote presentations from industry leaders
• Presentations from some of the region’s top existing and emerging medical device companies
• Workshops on a variety of topics including critical business issues affecting those within the industry
• Panel discussions by VCs and business development professionals, as well as a CEO Roundtable
• Numerous industry networking opportunities

For more information about the conference, sponsorship opportunities, presenting company application or registration, visit www.semdaconference.com.

About SEMDA
The Southeastern Medical Device Association (SEMDA) is a non-profit association that supports and promotes the medical device companies in the Southeast. Created in 2004, the association provides a unique resource and networking opportunity for medical device companies, entrepreneurs, inventors, physicians, and investors interested in accelerating the growth of the medical device industry in the Southeast. For more information, visit www.semda.net

Click here to see all recent news from this company

SCOTTSDALE, AZ–(Marketwire – December 7, 2010) – Stat Health Services Inc. and Scottsdale Healthcare announced today that they are offering Stat Health’s innovative STAT DOCTORS™ eHealth service as a supplemental health and wellness benefit for Scottsdale Healthcare’s employees and their covered dependents. 

Scottsdale Healthcare is the city of Scottsdale’s largest employer, operating three hospitals, a cancer center and several ambulatory care facilities with approximately 10,000 covered lives included in its employee medical plan. The agreement is Stat Health Services’ first contract with a major employer.

Like a virtual house call, STAT DOCTORS offers online on-demand care from a physician for many non-emergency minor illnesses or conditions. Effective today, Scottsdale Healthcare is launching the new employee benefit, just in time for the cold and flu season.

“With STAT DOCTORS our health plan participants will have the convenience of online access to board certified emergency physicians for care of common minor medical conditions, any time of the day or night. We believe this will be a popular benefit that our employees will take advantage of when they need care,” says Carol Henderson, senior vice president/chief talent officer for Scottsdale Healthcare.

55 percent of the 114 million visits to an emergency room are for non-emergencies¹. STAT DOCTORS leverages the Internet, advanced and proprietary technologies — including secure single sign-on, electronic health records (EHRs), ePrescribing and video conferencing — to bring patients a modern day virtual house call for treating minor medical emergencies.

By offering STAT DOCTORS, employers may benefit from increased employee satisfaction and retention, reduced employee absenteeism and decreased costs. Hospital employers such as Scottsdale Healthcare are also expected to benefit from their employees utilizing the STAT DOCTORS eHealth service for urgent care needs instead of hospital emergency rooms.

“In the past, patients had no choice but to either delay treatment or waste precious time and money waiting in emergency rooms or urgent care centers, exposed to seasonal viruses,” explains Alan C. Roga, M.D., Chairman and CEO of Stat Health. “Our STAT DOCTORS service solves this problem by using advanced technologies to provide convenient access to quality health care, 24 hours a day, 7 days a week.”

¹ “Addressing the Problem of Low Acuity Non-Emergent ER Visits,” Mercer Human Resources Consulting, January 2006.

About Scottsdale Healthcare
Scottsdale Healthcare is the community-based, nonprofit parent organization of the Scottsdale Healthcare Osborn Medical Center, Scottsdale Healthcare Shea Medical Center and Scottsdale Healthcare Thompson Peak Hospital, Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale Healthcare Research Institute and Scottsdale Healthcare Foundation. A leader in medical innovation, talent and technology, Scottsdale Healthcare was founded in 1962 and is based in Scottsdale, Arizona. For more information, visit www.shc.org.

About Stat Health Services Inc.
Stat Health Services Inc. is an eHealth services company. Its STAT DOCTORS™ service provides members convenient and affordable online access to emergency medicine physicians for the diagnosis and treatment of urgent common minor medical conditions. STAT DOCTORS™ brings patients a modern day virtual house call. By providing such features as a secure single sign-on, a virtual waiting room, online medical consultations (eVisits), electronic health records (EHRs), and electronic prescribing (ePrescribing), STAT DOCTORS™ delivers a personalized, secure and superior health care experience. Stat Health’s network of emergency medicine physicians includes top board certified physicians who share a passion for delivering high quality health care, efficiently and effectively, by using the Internet and advanced technologies to treat today’s connected patients. Stat Health is headquartered in Scottsdale, Arizona. For more information, visit www.STATDOCTORS.com.

SAN DIEGO, CA–(Marketwire – December 7, 2010) – Mitchell International, Inc., a leading provider of information, workflow and performance management solutions to the Property & Casualty (P&C) claims and Collision Repair industries, today announced the successful close of its purchase of Ingenix’s P&C medical bill review (MBR) business. The purchase places Mitchell Workers’ Compensation Solutions (WCS) business and its SmartAdvisor™ medical bill review platform in a market leadership position, enabling the company to deliver to the insurance and managed care related industries advanced technology solutions with a proven track record of streamlining medical claims operations and improving cost containment.

“Since the intent to purchase the Ingenix MBR business was announced this October 20, Mitchell has experienced broad market acceptance and customer buy-in, the result of a carefully planned business and technology transition strategy that is being deployed within the context of Mitchell’s stable position and long-term experience in the P&C marketplace,” said Nina Smith-Garmon, senior vice president and general manager of the Mitchell Workers’ Compensation Solutions Division.

Smith-Garmon added, “The positive feedback we have received at the recent National Workers’ Compensation and Disability Conference® & Expo indicates that Ingenix P&C MBR customers anticipate a smooth, successful transition to Mitchell and the SmartAdvisor medical bill review technology platform. We will continue to enhance our solution for all our customers by adding to our already-extensive Preferred Provider Organization (PPO) networks and compliance expertise via strategic partnerships and acquisitions.”

Mitchell SmartAdvisor is a comprehensive bill review solution for workers’ compensation that leads the industry in its unique combination of performance software, client services, and best-in-class partnerships. Available through licensed or software-as-a service model, SmartAdvisor’s unique capabilities include customizable workflow modeling, Capstone® business decision rules engine, data analytics and reporting tools, Claims Examiner Portal for fast, secured, real-time access to bill data, and a proven technology platform that delivers on average 50-70% straight-through processing for improved efficiencies and lower costs. Visit www.mitchell.com/smartadvisor for more information or contact Mitchell Workers’ Compensation Solutions directly at 1-800-421-6705 to schedule a demo of the SmartAdvisor bill review system.

About Mitchell International, Inc.
Mitchell International (www.mitchell.com) is a leading provider of information and workflow solutions to the Property & Casualty claims and Automotive Collision Repair industries. The company’s comprehensive solution portfolio streamlines the entire auto physical damage, bodily injury and workers’ compensation claims processes. Mitchell enables millions of electronic transactions between more than 30,000 business partners each month to enhance partner productivity, profitability, and customer satisfaction.

About Mitchell Workers’ Compensation Solutions Division
Mitchell Workers’ Compensation Solutions (WCS), a division of Mitchell International, is a leading provider of workers’ compensation cost containment technologies and services. Insurance payers and other clients rely on Mitchell WCS’s best-of-breed medical bill review platform, the SmartAdvisor Software Suite, to improve their medical cost savings results. For more information, please visit www.mitchell.com/smartadvisor.

Click here to see all recent news from this company

SAN DIEGO, CA–(Marketwire – December 7, 2010) – Medistem Inc. (PINKSHEETS: MEDS) announced today the appointment of Dr. Vladimir Bogin as President and Chairman of the Board, Dr. Sergey Sablin as Vice President and Board Member, and Vladimir Zaharchook as Vice Chairman of the Board and Board Member. These changes were brought about as the result of a stock purchase agreement changing majority ownership of the company. 

“Dr. Sablin, who has a track record of excellence in drug discovery and development, is a founder of Selena Pharmaceuticals and a co-founder of Medivation, companies that advanced Dimebon, a Phase III technology that resulted in a deal with Pfizer with an over $200 million in the upfront payment. Dr. Bogin, a licensed physician with training from Brown and Yale, founded the contract research organization (CRO) Cromos Pharma, and has held Director-level positions with Big Pharma. Mr. Zaharchook is a successful businessperson and strategist. I am happy to entrust the future of our company in the hands of these experienced professionals,” said Dr. Neil Riordan, founder and former President and Chairman of Medistem, who resigned along with board member Dr. Roger Nocera as part of the acquisition. Dr. Riordan remains a shareholder and collaborator of Medistem. 

Medistem was founded in 2005 by Dr. Riordan as a developer, licensor, and licensee of adult stem cell therapeutics. To date technologies developed by Medistem have been used in more than 900 patients internationally. Currently Medistem, together with the Indiana company General Biotechnology, is nearing completion of additional experiments requested by FDA to allow for clinical trial initiation as part of its filed IND BB-13898 covering the use of Medistem’s “Endometrial Regenerative Cell” (ERC) product in patients at risk of amputation. 

ERC are a novel stem cell population isolated from menstrual blood that the company has demonstrated is capable of generating heart, brain, lung, liver, pancreatic, bone, muscle, blood vessel and cartilage tissue. Advantages of ERC include: a) lack of need for donor matching, allowing for “off the shelf” use; b) ability to be injected intravenously; and c) economical production in large scale.

“Dr. Riordan has pioneered the development of practical stem cell based products for treatments of debilitating conditions ranging from Multiple Sclerosis, to Duchenne Muscular Dystrophy, to Heart Failure. The intellectual property portfolio for these products, which are the basis of Medistem’s US-based developmental efforts, provide a deep pipeline of therapeutic candidates,” said Dr. Bogin.

“In contrast to companies who perform research for the sake of research, Medistem’s technologies are actually benefitting patients today, unfortunately only outside of the US. I was attracted to Medistem’s desire to make these treatments available to patients through the tried and tested FDA regulatory route,” said Mr. Zaharchook.

“The fact that Medistem’s ERC cells can be shipped to any facility in the US and administered without need for complex cell processing or injection procedures makes this stem cell product very attractive from a commercialization perspective,” said Dr. Sablin.

About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. 

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

id=”nav_links”>

SOMERSET, NJ–(Marketwire – December 6, 2010) – TeamStaff, Inc. (NASDAQ: TSTF), a leading logistics and healthcare services provider to the Federal Government and Department of Defense announced today that its President and Chief Executive Officer, Mr. Zach Parker, will deliver a presentation to investors at the Third Annual LD MICRO Conference on Thursday, December 9, 2010 at 3:00pm PST. The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles, California. A copy of the presentation will be made available in the Investor Relations section of the TeamStaff website (http://teamstaff.com/investor-relations) and also furnished as an exhibit to a Current Report on Form 8-K to be filed by the Company with the SEC.

“I’m pleased to present the TeamStaff story at this year’s LD MICRO investor conference as we believe we have laid the proper foundation to facilitate growth especially into adjacent markets with new customers, like the DoD. I am thankful to participate in this investor conference and I am looking forward to meeting with attendees who specifically have an interest in microcap companies,” said Zach Parker, Chief Executive Officer of TeamStaff.

“We are very pleased to have TeamStaff present at our third annual event,” said Chris Lahiji, President of LD MICRO. “I take pride in having an event that showcases companies of all sizes, in all industries. TeamStaff is a great addition to our roster this year.”

For more information on the conference or to register for the event, please visit http://www.ldmicro.com or call (408) 457-1042.

About TeamStaff, Inc.

TeamStaff serves clients and their employees throughout the United States as a full-service provider of logistics and healthcare support services. TeamStaff specializes in providing high quality healthcare, logistics, and technical services to Federal agencies and the Department of Defense. For more information, visit the TeamStaff corporate web site at www.teamstaff.com or the TeamStaff Government Solutions web site at www.teamstaffgs.com.

This press release contains “forward-looking statements” as defined by the federal securities laws and involve numerous risks and uncertainties. TeamStaff’s actual results could differ materially from those described in such forward-looking statements as a result of such risks and uncertainties. For a discussion of such risks and uncertainties, see “Risk Factors” in the Company’s periodic reports filed with the U.S. Securities Exchange Commission. The information in this release should be considered accurate only as of the date of the release. 

DEARBORN, MI–(Marketwire – December 6, 2010) – This year, more than 170,000 Michigan residents receive home-delivered health care from home health care providers, who make over 5 million home visits each year.

Many patients and their families prefer that their loved ones recuperate and/or receive rehab services for surgery, an injury or an acute illness in the comfort and familiar surroundings of their own homes. Trained clinicians, nurses, and therapists are able to provide the same level of attentive, compassionate and personalized in-home care as can be found outside.

Choosing a provider can often be a daunting and frustrating task. To aid the public, Dearborn-based Metro Home Health Care, a leading home health care provider in Michigan, is offering at no cost a Home Health Care Guide that provides basic information for people seeking a home health care agency.

The free booklet may be downloaded from the Metro Home Health Care website, www.metrohomehealthcare.com.

“We think the booklet offers specific things to look for in selecting a home health care agency, and what questions to ask before you make a decision,” said Dr. Agustin V. Arbulu, CEO of Metro Home Health Care. “Our mission has always been to provide best care available to the sick, the elderly or those recovering from surgery in their homes.”

Today’s home care professionals, volunteers, and modern medicine make it possible for people to stay in their homes longer and enjoy an improved quality of life.

Home health care has grown far beyond basic or simple professional nursing and home care aide services. Modern home care agencies like Metro Home Health Care offer a comprehensive scope of services including skilled nursing, physical, occupational, speech therapies, medical social work services, specialty wound care nursing, dietary education, and personal care.

“Metro Home Health Care always has the goal of independence in mind when caring for our neighbors,” said Arbulu.

Home care services are paid for by public and private sources, or directly by patients and their families. Medicare and state-run Medicaid are significant payers and often pay 100 percent of home health services for patients who qualify for such services. Third-party payers include commercial insurance, managed care organizations, and workers’ compensation. Despite deep cuts in government funding, home care continues to be the preferred means of receiving quality health care services for millions of Americans.

With offices in five cities covering 10 counties, Metro Home Health Care provides comprehensive in-home and supportive services for the entire Michigan lower peninsula to acute and chronically ill patients and their families. For more information, please call 313-336-6303 or 800-462-5632, or visit www.metrohomehealthcare.com.

Click here to see all recent news from this company

CHICAGO, IL–(Marketwire – December 6, 2010) – Physicians in three out of four medical groups of Resurrection Health Care Preferred (RHCP) have earned 11 blue stars — a perfect score — in the 2010 Blue Star Report. The report is a ranking of HMO contracting medical group physicians that have documented high levels of performance in providing patient care from Blue Cross Blue Shield of Illinois (BCBSIL). The Resurrection Health Care Preferred groups earning 11 stars are: Saint Joseph Health Preferred, Saint Mary and Elizabeth Health Preferred and Saint Francis Health Preferred. One group, Resurrection Health Preferred, earned 9 out of 11 stars.

Of the 96 Chicagoland medical groups surveyed, only eight received all 11 blue stars, three of which were part of Resurrection Health Care Preferred. All of the Resurrection Health Care Preferred medical groups received the Blue Ribbon designation — awarded for high patient satisfaction. All of the patients who had RHCP doctors rated their overall satisfaction with their doctor at above 91%.

The medical group’s doctors earn a blue star every time they meet or exceed the target care goal in each of the eleven reporting categories, including asthma care, breast cancer screenings, cardiovascular disease, childhood immunizations, controlling high blood pressure, colorectal screenings, diabetes care, influenza vaccinations, mental health follow-up, cervical cancer screenings and patient safety.

For more information about making Resurrection Health Care Preferred your choice for all your health care needs, call 773-572-8300 and ask for Member Services or visit us at http://www.reshealth.org/findadoctor/why_rhcp.cfm

Resurrection Health Care is the largest Catholic health care system in Chicago with over 100 sites of care. http://www.reshealth.org/

Follow us on Twitter: http://twitter.com/RHC_Outpatient
Visit our YouTube channel: http://www.youtube.com/user/ResurrectionHealth
Join us on Facebook: http://www.facebook.com/pages/Resurrection-Health Care/73879323438?ref=ts  

Click here to see all recent news from this company

THOUSAND OAKS, CA and POTTSTOWN, PA–(Marketwire – December 6, 2010) –  Amgen Inc. (NASDAQ: AMGN) http://www.amgen.com awarded IT&E International http://www.iteinternational.com/ top honors as Veteran-Owned Small Business Contract Staff Supplier in its Supplier Diversity Program.

According to Audrey Porter, IT&E International Vice President, “A special flag-raising ceremony at Amgen’s Thousand Oaks, California headquarters hosted by the Supplier Diversity program was attended by Rocky Chavez, California Secretary of Veteran Affairs, Debbie Gregory Co-Chair of the Veteran and Military Business Owners Association, Ryan Funderburg of IT& E International, and senior Amgen leadership.

“We are extremely grateful to Amgen for this recognition,” continued Ms. Porter, “and appreciate the opportunities to help the company make significant strides in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses,” she said.

About Amgen’s Supplier Diversity Program

Amgen has established a Supplier Diversity Program to ensure that small businesses are not excluded from participating in the supply of goods and/or services required by Amgen. Amgen is committed to identifying and awarding contracts to small, disadvantaged, women-owned businesses consistent with Amgen’s requirements. Amgen strives to identify, develop, and utilize small, disadvantaged, veteran, disabled veteran, and women-owned business enterprises, as well as Historically Underutilized Business Zones (HUBZone), in our procurement program. Amgen’s intent is to support economic development efforts to the extent that jobs may be provided, entrepreneurship may be advanced, and useful goods and/or services may be procured at competitive prices.

About IT&E International

IT&E International offers global regulatory compliance and validation services throughout the product development lifecycle. Consulting services include regulatory planning, providing skilled personnel for development operations, data management to ensure FDA compliance, and validation of new pharmaceutical manufacturing facilities. IT&E International provides our qualified, technical employees to work at pharmaceutical, biotech and life sciences organizations site under client supervision in FDA regulated areas. The company is headquartered at 1610 Medical Drive, Suite 210Pottstown, PA 19464; tel: (610) 340-2012; fax: (610) 340-2007; www.iteinternational.com

TUSTIN, CA–(Marketwire – December 6, 2010) – In its 12 year history, cardiovascular, dermatology and metabolic CRO Integrium has developed and managed over 150 successful clinical trials for clients, consistently beating patient enrollment goals and reducing costs. Integrium provides a therapeutic focus based on deep experience in cardiovascular, dermatological and metabolic trials of all sizes in regions around the world. On the basis of this experience the company offers a full range of services that combine innovative cutting-edge science and technology with practical clinical operations and involve working hands-on with clients, investigators and vendors to deliver high quality service with a sense of immediacy.

Integrium’s smaller size enables it to be far more nimble, and develop a personal rapport and trust with its clients in a way that “mega CROs” simply cannot. 2011 will mark the beginning of Integrium’s 13th year in this highly competitive market, a year the company will usher in with a large cadre of return clients and a team of passionate employees whose dedication is underscored by some of the lowest employee turnover in the business. Its exceptional performance recently caught the attention of the prestigious British pharmaceutical industry journal Scrip Clinical Research, which included Integrium in a cover story on specialty CROs, citing the launch of its dermatological practice as an example of a niche strategy worth watching.

Key Integrium Milestones/Metrics

• 12-year anniversary
  • Founded in 1998 by clinical research thought leaders Dr. David H.G. Smith, MD and Dr. Joel M. Neutel, MD. Dr. Smith and Dr. Neutel continue to lead the company today.
  • Established formal alliances with regional partner CROs in Europe, Australia and India, with numerous additional Integrium locations in North America and South Africa
• 150 successful clinical trials for clients
  • Tightened patient enrollment timelines dramatically and reduced study spend for clients such as Graceway Pharmaceuticals and Resverlogix
  • Consistently differentiated itself by demonstrating a deep understanding of the complexities and nuances of clinical research in its three core focus therapeutic areas: cardiovascular disease, metabolic disease and dermatology
  • Underscoring its success in these trials, 63% of Integrium’s business is with clients for whom it has managed clinical trials before
• Added Dermatology Clinical Research Group in June 2010
  • Helps Integrium clients design scientifically rigorous yet feasible dermatology studies, leveraging its relationships with reliable, high-quality investigators to help identify and recruit study patients, and effectively manage their studies from start to finish
  • Led by noted dermatology drug development expert Dr. Mary Spellman
• In a business where qualified, motivated professionals are critical to success and turnover is high, Integrium has some of the lowest turnover in the industry, with over 90% of the team remaining intact

Commentary
Dr. David Smith, MD, Founding Partner and Chief Medical Officer, Integrium: “Patient recruitment, enrollment and retention continue to represent a critical bottleneck in clinical research and drug development. We are proud of the results we’ve achieved with clients like Graceway and Resverlogix to ensure that they have the patient subjects they need to get the highest-quality data to run better, safer trials.”

Eileen McAuley, RN, BS, MPA, Chief Operating Officer, Integrium: “We take our mission statement seriously, focusing on integrity as a core value. This translates into our dedication to personalized service from the start of a client’s clinical trial to its completion, rigorous scientific protocols, and unyieldingly high research standards. We are not striving to be the biggest CRO — just the best.”

Dr. Sharon Levy, MD, Senior Vice President of Product Development, Graceway Pharmaceuticals: “Integrium’s keen understanding of our specific therapy areas allows us to stay focused on our primary trial objectives. For a multi-center Phase 2 trial they helped us enroll and randomize many more patients than we thought possible — and did so with a very small drop-out rate and 19 weeks ahead of schedule.”

Dr. Allan Gordon, MD, Ph.D, Senior Vice President, Clinical Development, Resverlogix: “Integrium understands that trial efficiencies come from the ground up. The services team understood that we required a ‘true’ partnership and that success would come from understanding our needs and the complexities inherent in running a 40-site study — and their results exceeded our expectations. That they reduced our cycle so dramatically — by nearly six months — allowed us to come in under budget and see the site results we hoped for.”

Resources

• Press release announcing successful trials with Graceway Pharmaceuticals and Resverlogix
• Press release announcing launch of Dermatology Clinical Research Group
• Overview of Integrium’s expertise as a cardiovascular, dermatology and metabolic CRO
• Follow Integrium on LinkedIn

About Integrium, LLC
Integrium is a therapeutically-focused, full-service contract research organization that specializes in dermatology, cardiovascular and metabolic clinical research. It has a strong reputation for delivering high-quality management of global clinical development programs and service to its clients. Combining the Integrium Clinical Excellence (ICE) study start-up and management methodology, and therapeutic expertise leads sponsors to more confident, better-informed drug and device development decisions. For more information please visit http://www.integrium.com.

CAMBRIDGE, MA–(Marketwire – December 6, 2010) – InterSystems Corporation, the global leader in software for connected healthcare, today announced that the University of Colorado Hospital (UCH) has chosen the InterSystems Ensemble® rapid integration and development platform for enterprise-wide integration.

InterSystems specializes in advanced integration, database, and business intelligence technologies for breakthrough applications. UCH is recognized as one of the leading hospitals in the nation and is consistently recognized among the top hospitals in the country by U.S. News & World Report. Most recently, UCH has been cited as one of the top 10 academic medical centers in the country based on quality, patient safety and patient satisfaction, according to the 2010 Quality and Accountability Performance Scorecard, released by the University HealthSystems Consortium.

Strategy Change Drives Integration Platform Search

“For years, our strategy had been tied to the best-of-breed concept, which resulted in a very decentralized system with more than 150 unique interfaces,” said Peggy Dalious, UCH Applications Director. “Then, we made the decision to move to the InterSystems CACHÉ-based Epic Systems electronic health record application, which required major alterations to our IT plans.”

“We recognized that the integration engine represented a key piece of our infrastructure before we entered what is going to be a mass application overhaul,” Dalious continued.

The change in strategy came at a time when UCH was increasingly uneasy about its legacy integration platform, noted Dalious. The acquisition of the product’s company by another vendor, followed by the acquisition by yet another vendor, added a layer of complexity to working with the product.

“Our interface engineers had heard about Ensemble and thought it might be the right integration option for UCH,” Dalious said. After extensive research and interaction with multiple Ensemble customers, “we had a strong, sensible case for moving to Ensemble.”

The foundation for the Ensemble transition was developed based on a proof-of-concept project. UCH specified two difficult interfaces that would have to be built via Ensemble for the POC. InterSystems reviewed the interfaces onsite and defined the requirements, with UCH software specialists building the interfaces under the guidance of the InterSystems team.

Moving Forward on Solid Foundation

Following the success of the proof-of-concept, UHC has gone live with approximately 35 Ensemble-based interfaces with a core group of applications including human resources and ERP systems that will not be replaced by the Epic implementation. Plans are to go live in 1Q11 with the Epic ambulatory clinics application with Epic outpatient and inpatient modules and a total of about 85 interfaces rolling out through 3Q11.

“We’re already beginning to see how we can use other Ensemble capabilities once the interface migration from the legacy platform is complete,” Dalious said. “We know that features such as workflow management and business activity monitoring are available in Ensemble and we plan to take advantage of those facilities in the future.”

“Ensemble delivers the advanced technology required for strategic breakthroughs like the one now being realized by UCH,” said Paul Grabscheid, InterSystems Vice President of Strategic Planning. “As the healthcare industry continues to rapidly evolve, we are committed to partnering with our customers who leverage our software to optimize care delivery.”

About InterSystems

InterSystems Corporation is a global software technology leader with headquarters in Cambridge, Massachusetts, and offices in 23 countries. InterSystems provides advanced software technologies for breakthrough applications. InterSystems CACHÉ® is a high performance object database that makes applications faster and more scalable. InterSystems Ensemble® is a seamless platform for integration and the development of connectable applications. InterSystems HealthShare™ is a platform that enables the fastest creation of an Electronic Health Record for regional or national health information exchange. InterSystems DeepSee™ is software that makes it possible to embed real-time business intelligence capabilities in transactional applications.

InterSystems is the world’s #1 vendor of database and integration technologies for healthcare applications. InterSystems products are used by thousands of hospitals and labs worldwide, including all 14 hospitals on the Honor Roll of America’s Best Hospitals as rated by U.S. News and World Report. For more information, visit InterSystems.com.

About University of Colorado Hospital

University of Colorado Hospital is the Rocky Mountain region’s leading academic medical center, and has been recognized as one of the United States’ best hospitals, according to U.S. News & World Report. It is best known as an innovator in patient care and often as one of the first hospitals to bring new medicines to patients’ bedsides. Located at the Anschutz Medical Campus in Aurora, Colo., the hospital’s physicians are affiliated with the University of Colorado School of Medicine, part of the University of Colorado system. For additional information, go to www.uch.edu.

SAN DIEGO, CA and NEW YORK, NY–(Marketwire – December 6, 2010) – Mitchell International, Inc., a leading provider of information, workflow and performance management solutions to the Property & Casualty claims and Collision Repair industries and CoreChoice, the nation’s fastest growing specialty network devoted entirely to radiological services today announced the execution of a multi-year contract. Claims professionals, via Mitchell DecisionPoint^®, the leading medical bill management solution for 1^st and 3^rd party liability claims handlers, can now access the depth and breadth of the CoreChoice radiology network; which includes highly specialized services such as MRI (Open and Closed), Mammography, Sonogram, X-Ray, Nuclear Medicine services and CT, PET and Bone Scan services. This provides for an enhanced ability for insurers to ensure maximum value delivered to policyholders within their coverage limits via the benefits of pre-negotiated contract rates with CoreChoice facilities.

“CoreChoice is an established leader in the provision of a broad set of high quality radiological services,” said Dave Torrence, Senior Vice President and General Manager, Mitchell International. “Our relationship with CoreChoice is a natural and synergistic extension of the capabilities of both of our organizations to the benefit of our customers, who elect to implement CoreChoice, and — most importantly — to injured parties. We know and understand that specialized procedures, including radiological services are driving costs up nationally and we’re excited about extending our capabilities in offering CoreChoice.”

Mitchell is pleased to provide additional benefits for its customers through this new agreement with CoreChoice, including:

• The service and quality of care results they demand in their claims handling organizations via the ability to provide injured parties — including those who might not otherwise have convenient access to such an extensive range of top quality radiological services — the benefit of more than 6,000 CoreChoice imaging centers throughout the nation, including Washington D.C. and Puerto Rico;
• Maximum efficiency and productivity of claim handlers. DecisonPoint provides a “single source solution” enabling claims professionals to save time by reducing the use of a variety of disparate claims handling solutions as well as the high amounts of manual processing often required to access the benefits of specialty medical networks;
• Elimination of billing negotiations as medical billings from CoreChoice facilities are quickly paid via pre-established contractual rates; and
• A fully integrated and modern medical bill review technology solution that is compliant with standard HIPAA and ANSI X12 data transmission requirements.

Accessibility to CoreChoice networks via Mitchell’s state-of-the-art bill review offerings provides CoreChoice network members significant expansion opportunities. “There is exponential growth in the use of radiological procedures in healthcare,” said Steven F. Gass, Chief Executive Officer, CoreChoice. “CoreChoice is dedicated to providing injured parties the highest quality radiological services available and our Mitchell relationship offers us significant opportunities to expand our reach to assist injured parties to receive prompt, effective, proper and reasonably priced medical care.”

About Mitchell DecisionPoint

Mitchell DecisionPoint® is the leading medical bill management solution for 1^st and 3^rd party liability claims handlers reviewing more than 13 million medical bills each year representing more than $11 billion in medical provider billed charges. DecisionPoint is in use by more than 40 top US property casualty insurers including 8 of the 10 largest automobile insurers representing more than 60 percent of direct written premium in the personal auto lines market.

About Mitchell International, Inc.

Mitchell International (Mitchell) is a leading provider of information and workflow solutions to the Property & Casualty claims and Automotive Collision Repair industries. The company’s comprehensive solution portfolio streamlines the entire auto physical damage, bodily injury and workers’ compensation claims processes. Mitchell enables millions of electronic transactions between more than 30,000 business partners each month to enhance partner productivity, profitability, and customer satisfaction. For more information please visit www.mitchell.com

About CoreChoice

CoreChoice combines the talents and expertise of medical, technology, and insurance industry professionals to provide a new level of radiology network service. Our philosophy is to provide the largest radiology specialty network in the United States with fair and equitable pricing as well as a prompt pay mechanism for our participating network facilities. For more information please visit www.corechoice.net.

BALTIMORE, MD–(Marketwire – December 6, 2010) – eMarkets Group LLC, the distributor of HealFast® Therapy, disposable drug-free anti-inflammatory medical devices manufactured by BioElectronics Corporation (PINKSHEETS: BIEL), today announced the introduction of a new Quick Relief Loop. The Quick Relief Loop will be available at the breakthrough price of $15.00 for 100 hours of continuous pain relief therapy. 

The new product is on display this week at the annual convention of the American Association of Equine Practitioners in Baltimore.

“The award-winning BioElectronics team has made cost-reduction engineering improvements that enable the breakthrough new pricing,” said Mary K. Whelan, President of eMarkets Group. “BioElectronics technology was cited by the Wall Street Journal as one of the best innovations of 2009. Now the Quick Relief Loop pricing makes cost-effective, drug-free pain relief available to much larger markets.” 

Whelan explained that the new Quick Relief technology is available in the US only in the veterinary market initially. HealFast Therapy is currently in use in leading equine treatment centers and has been recommended by both equine and small animal veterinarians.

Mac Stein is a physical therapist who has used HealFast Therapy extensively. “I have had very good results using the patch on a variety of acute and chronic conditions. The new lower cost unit will be ideal for problems like strains and tendonitis as well as wounds and abscesses which respond rapidly to the continuous application of PEMF Therapy.” Mac Stein will be available to speak with veterinarians at the AAEP Conference Exhibit Hall, booth 704.

The Company said that earlier PEMF therapy delivery systems required cumbersome devices or repeated office visits. The HealFast Therapy Quick Relief patch joins the HealFast family of PEMF products that are available in a range of shapes and sizes for different veterinary uses and are priced from $89.95 for long lasting units with on/off switches to the new $15.00 unit for 100 hours of continuous treatment.

eMarkets Group, the global veterinary distributor of BioElectronics products, markets and sells the product through veterinarians and therapists and on its web site, http://www.healfasttherapy.com. HealFast Therapy is developed and manufactured by BioElectronics Corporation (PINKSHEETS: BIEL), which has extensive worldwide patents and patents pending.

For more information visit http://www.healfasttherapy.com or call 1-888 9 HEALFAST (1-888-943-2532) or 551-200-5586.

About HealFast Therapy
HealFast Therapy is a wearable patch with an embedded microchip that delivers continuous PEMF therapy for horses, cats and dogs. HealFast Therapy is a wearable, disposable patch with an embedded microchip that delivers continuous PEMF therapy for horses, dogs and cats. The patch is a state-of-the-art safe treatment option for relieving pain, edema and inflammation as well as enhancing repair of various types of wounds. HealFast Therapy is distributed by eMarkets Group, LLC, North Caldwell, NJ.

About BioElectronics Corporation
BioElectronics Corporation is the developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal complaints, the Allay™ menstrual cycle pain therapy, and RecoveryRx for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and swelling. For more information, please see www.bielcorp.com.

Click here to see all recent news from this company

VANCOUVER, BC–(Marketwire – December 6, 2010) – Digital Payment Technologies (http://www.digitalpaytech.com) (DPT), a leading supplier of parking technology and solutions, today announced that the city of Houston, Texas, will roll out an additional 250 of the company’s LUKE pay stations, marking a significant expansion of an already successful deployment program. On December 8, DPT will host a webinar with Houston’s director of parking management, Liliana Rambo, CAPP, who will share insights gained from her experience planning and implementing a large-scale parking technology transition that has been favorably met by officials and the public in the fourth largest city in the U.S.

The 250 new LUKE pay stations will be configured similarly to those in the original deployment that began in 2006. They will connect to the city’s back-end parking management systems via Wi-Fi, will accept coins, bills and credit cards, and in the future will be able to accept payment by cellular phone. This brings the total number of DPT pay stations in Houston to 1,000, and marks yet another milestone in a tremendously successful program.

“DPT pay stations enable Houston’s parking management division to meet its objectives of delivering superior service to consumers and optimizing operational efficiency,” said Rambo. “In these difficult economic times, the operational efficiency and increased revenue made possible by these advanced parking systems have enabled the city to continue to fund many important municipal programs.”

Houston’s project was initiated to replace outdated single- and double-head parking meters, improve the parking experience for the public, reduce traffic congestion, increase parking turnover and improve the bottom line. By implementing a comprehensive rollout plan that included a variety of communications strategies with key stakeholders throughout the process, Houston’s Parking Management Division has secured some impressive results, including:

• 80 percent revenue increase without an increase in parking rates.
• 33 percent productivity improvement for meter operations staff.
• 1,000 more paid citations per month, equal to $58,000 in revenues, due to citations being upheld in adjudication. The new technology leaves less room to dispute tickets.

DPT’s December 8^th webinar will provide additional details and best practices from this $15.4 million advanced parking project that will be useful to municipal, county and state government departments, as well as private parking operators responsible for parking and enforcement. Free registration is available at: http://event.on24.com/r.htm?e=265402&s=1&k=8C1A49910D44B77405A4E608E0F0843D&partnerref=dpt1

“The City of Houston’s use of multi-space pay stations is a testament to the positive impact that smart parking initiatives can have on a city,” said Alan Menezes, vice president of product management and marketing with Digital Payment Technologies. “There is a great opportunity for cities that still rely upon single-head parking meters to institute a similar parking plan and reap the benefits. Our customizable pay stations, back-end services and support and seamless integration with leading industry partners put DPT in the unique position of offering a complete parking solution composed of best-in-class components. Furthermore, DPT has significant experience helping large and small municipalities ensure a smooth transition as they embrace multi-space parking.”

Houston/DPT Webinar Details:
Date: Wednesday, December 8, 2010
Time: 2:00 p.m. EST / 11:00 a.m. PST
Cost: Free
Register: http://event.on24.com/r.htm?e=265402&s=1&k=8C1A49910D44B77405A4E608E0F0843D&partnerref=dpt1 

About Digital Payment Technologies
Digital Payment Technologies (DPT) is an innovative leader in the design, manufacture, and distribution of electronic parking meters, management software, and online services for the parking industry. DPT products provide complete financial tracking, control, and reporting on parking revenue collected by cities, municipalities, universities, parking management companies, private operators, and national parks, from customer payment through to bank deposit. In 2007, DPT was named Emerging Company of the Year by the British Columbia Technology Industry Association, and has been included on multiple Deloitte Technology Fast 50 and Fast 500 lists as one of the fastest growing high technology companies in North America. For more information visit: http://www.digitalpaytech.com

Click here to see all recent news from this company

OTTAWA, ONTARIO–(Marketwire – Dec. 6, 2010) – As Canada looks to the renewal of its Health Accord in 2014, public health leaders are hopeful room can be found for the creation of a national immunization registry, says Debra Lynkowski, Chief Executive Officer, Canadian Public Health Association (CPHA).

“Unfortunately, our typically Canadian response to broader immunization issues has resulted in a patchwork of approaches across the country,” said Lynkowski. “Now, as we approach the renewal of the Health Accord in 2014, is the time for a harmonized, national immunization registry.”

While we recognize additional funding may seem an improbable request of governments in the current fiscal environment, a national immunization strategy that includes at its core a national registry, one supported by all provinces and territories, would ensure Canadians are equitably protected against vaccine-preventable illnesses, regardless of where they live, their age or their socio-economic status.

“All Canadians should have equal access to immunizations for vaccine-preventable diseases. Where you live should have no bearing on access to immunization programs,” said Lynkowski.

Improvements stemming from a national immunization strategy would include harmonization of childhood immunization schedules across the country, aligned introduction of new vaccines, and equal access to vaccines across all provinces and territories. The systematic collection of immunization data in a national immunization registry will modernize the way jurisdictions communicate patients’ immunization histories and help to ensure coverage rates are high enough throughout the country to best protect Canadians.

A national strategy would also promote better opportunities for research, vaccine promotion and improved education of health care providers and the general public, said Lynkowski. Currently, Canada lacks a harmonized cross-country routine immunization schedule.

“Simply put, it is better to prevent disease and illness than to have to treat it,” said Lynkowski.

These recommendations are a result of unprecedented and ongoing dialogue with government leaders, industry and public health and health care stakeholders.

Founded in 1910, the Canadian Public Health Association (CPHA) is the independent voice for public health in Canada with links to the international community. As the only Canadian non-governmental organization focused exclusively on public health, CPHA is uniquely positioned to advise decision-makers about public health system reform and to guide initiatives to help safeguard the personal and community health of Canadians and people around the world. With a diverse membership representing more than 25 professions, a track record of success, a collaborative approach and national reach, CPHA is Canada’s Public Health Leader.

Background

CPHA has been working actively with stakeholders to improve the environment for a national immunization strategy that would protect Canadians against vaccine preventable diseases. To facilitate an ongoing dialogue, CPHA organized a roundtable discussion in 2009 with stakeholders and has since participated in various information-sharing activities organized by leading national organizations.

In addition, to ensure timely response to last year’s H1N1 pandemic, the CPHA, in collaboration with the Public Health Agency of Canada, the Canadian Medical Association, College of Family Physicians of Canada and the National Specialty Society for Community Medicine developed “PANDEMIC H1N1: Fast facts for front-line clinicians.”

In response to a significant demand for information in addition to what was available from the Government of Canada, CPHA established the Canadian H1N1 Information Clearinghouse as an additional, non-governmental source of reliable information for Canadians.

As secretariat for the Canadian Coalition for Immunization Awareness and Promotion, CPHA facilitates and coordinates the activities of the Coalition to minimize duplication and ensure that Canadians receive consistent immunization messages.

A backgrounder is available at the following address: http://media3.marketwire.com/docs/cpha-eng.pdf

OTTAWA, ONTARIO–(Marketwire – 6 déc. 2010) – Alors que le Canada songe au renouvellement de son Accord sur les soins de santé en 2014, les principaux intervenants en santé publique sont optimistes quant à la mise sur pied d’un registre national d’immunisation, déclare Debra Lynkowski, présidente-directrice générale de l’Association canadienne de santé publique (ACSP).

« Notre réponse typiquement canadienne aux problèmes d’immunisation plus vastes a malheureusement entraîné des approches diverses au pays », affirme Debra Lynkowski. « Maintenant, alors qu’on approche du renouvellement de l’Accord sur les soins de santé, en 2014, le moment est venu de mettre sur pied un registre national d’immunisation harmonisé. »

Nous reconnaissons qu’une demande de financement supplémentaire auprès des gouvernements peut sembler invraisemblable dans le présent contexte fiscal, mais une stratégie nationale d’immunisation basée sur un registre national, soutenu par toutes les provinces et les territoires, assurerait une protection équitable des Canadiens contre les maladies évitables par la vaccination, et ce, peu importe leur lieu de résidence, leur âge ou leur statut socio-économique.

« Tous les Canadiens devraient avoir un accès égal à l’immunisation contre les maladies évitables par la vaccination. Le lieu de résidence ne devrait pas avoir d’incidence quant à l’accès aux programmes d’immunisation », soutient Debra Lynkowski.

Les améliorations découlant d’une stratégie nationale d’immunisation comprendraient une harmonisation des calendriers de vaccination pour les enfants partout au pays, un alignement de l’introduction des nouveaux vaccins et une égalité d’accès aux vaccins dans toutes les provinces et territoires. La collecte méthodique de données relatives à l’immunisation dans un registre national d’immunisation modernisera la façon dont les autorités transmettent les dossiers d’immunisation des patients et aidera à assurer des taux de couverture suffisamment élevés partout au pays afin de mieux protéger les Canadiens.

Debra Lynkowski souligne qu’une stratégie nationale promouvrait aussi de meilleures possibilités de recherche, la promotion de vaccins, ainsi qu’une meilleure éducation des fournisseurs de soins de santé et du public. À l’heure actuelle, le Canada n’a pas de calendrier harmonisé de vaccination systématique pancanadienne.

« En bref, il vaut mieux prévenir les maladies que d’avoir à les traiter », conclut Debra Lynkowski.

Ces recommandations sont le résultat d’un dialogue continu sans précédent que tiennent les dirigeants du gouvernement et les principaux intervenants de l’industrie et des secteurs de la santé publique et des soins de santé.

Fondée en 1910, l’Association canadienne de santé publique (ACSP) est le porte-parole de la santé publique au Canada. L’indépendance de l’ACSP, ses liens avec la communauté internationale et le fait qu’elle soit la seule organisation non gouvernementale canadienne à se consacrer exclusivement à la santé publique la placent en position idéale pour conseiller les décideurs à propos de la réforme du réseau de santé publique et pour orienter les initiatives visant à protéger la santé individuelle et collective au Canada et dans le monde. Grâce à son effectif diversifié représentant plus de 25 professions, son efficacité démontrée, son approche de collaboration et son envergure nationale, l’ACSP est le chef de file canadien en santé publique. 

Contexte

L’ACSP travaille activement avec les principaux intervenants de l’industrie pour créer un contexte favorable à une stratégie nationale d’immunisation qui protégerait les Canadiens contre les maladies évitables par la vaccination. Pour faciliter un dialogue continu, l’ACSP a organisé une table ronde en 2009 avec les principaux intervenants et a depuis participé à diverses activités d’échange d’information organisées par d’importants organismes nationaux. 

En outre, pour assurer une réponse dans les meilleurs délais à la pandémie H1N1 de l’année dernière, l’ACSP, en collaboration avec l’Agence de la santé publique du Canada, l’Association médicale canadienne, le Collège des médecins de famille du Canada et la Société nationale de spécialistes pour la médecine communautaire, a mis au point l’outil « GRIPPE PANDÉMIQUE H1N1 — Aide-mémoire à l’intention des cliniciens de première ligne ».

En réponse à l’importante demande de renseignements en plus des renseignements déjà offerts par le gouvernement du Canada, l’ACSP a fondé des centres d’échange d’information canadiens sur la grippe H1N1 comme autre source non gouvernementale de renseignements fiables pour les Canadiens.

En tant que secrétariat pour la Coalition canadienne pour la sensibilisation et la promotion de la vaccination, l’ACSP fait office de facilitateur et de coordonnateur d’activités de la Coalition pour réduire au minimum les chevauchements et s’assurer que les Canadiens reçoivent des messages cohérents concernant l’immunisation.

Un document d’information est disponible à l’adresse suivante : http://media3.marketwire.com/docs/cpha-fre.pdf

NANCHANG, CHINA–(Marketwire – Dec. 3, 2010) – Hiru Corporation (PINK SHEETS:HIRU) (www.hirucorporation.com) subsidiary Shuangshi AHP Co. dispatched company representatives to evaluate the agricultural developments and increase company sales in the regions of Ganzhou, Yichun and Jian.

Shuangshi’s assistant general manager and sales manager met with several potential customers in the aforementioned regions to discuss the potential of Shuangshi products on the local markets, as the company works on gaining more exposure with Chinese farmers for their vaccination needs.

The representatives also negotiated with two new agricultural clients, each client reporting annual sales of approximately $30 million USD. Following these negotiations, Shuangshi AHP representatives supplied the customers with new HIRU products for testing and evaluation by the clients. Shuangshi AHP anticipates to gain more new clients as the company’s top quality animal vaccination products gain exposure in the market.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hiru Corporation that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project” and similar words and phrases are intended to identify such forward-looking statements. Hiru Corporation cautions you that any forward-looking information provided by or on behalf Hiru Corporation is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hiru Corporation’s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hiru Corporation’s control. In addition to those discussed in Hiru Corporation’s press releases, public filings, and statements by Hiru Corporation’s management, including, but not limited to, Hiru Corporation’s estimate of the sufficiency of its existing capital resources, Hiru Corporation’s ability to raise additional capital to fund future operations, Hiru Corporation’s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hiru Corporation’s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hiru Corporation does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

BURLINGTON, VT–(Marketwire – December 3, 2010) – Marathon Health today announced that C&S Wholesale Grocers, the largest grocery wholesaler in the country, will open an onsite healthcare facility at their headquarters in Keene, N.H. on December 6, 2010.

The C&S Healthy Living Wellness Center, which will be managed by Marathon Health, will serve employees and their families, including dependents over the age of six, within the Brattleboro, VT and Keene, NH area. Available services include acute and primary care, wellness and health promotion, health coaching, disease management, medication dispensing, and the Marathon eHealth Portal technology to support the delivery of care and coaching. The Center staff will include two nurse practitioners, a registered nurse and a medical assistant.

“Marathon Health shares our philosophy about healthcare responsibility and has the tools and programs to help improve the overall health of our workforce,” said Richard Cohen, C&S Chairman and CEO. The worksite healthcare initiative will be offered as part of the company’s Total Rewards health programs that encourage people to be active participants in their own health and healthcare.

“What is most important at Marathon Health is how we inspire people to understand and care about their health — it is the foundation of what we do. We are excited to help C&S enhance the culture of health and responsibility they have established,” said Jerry Ford, Marathon Health CEO.

About C&S Wholesale Grocers

C&S Wholesale Grocers of Keene, NH, is the largest food wholesaler and according to Forbes magazine, the 10th largest privately held company in the United States. The company distributes food to supermarkets, retail stores and military bases across the country.

Currently, C&S serves about 3,900 stores from more than 50 locations in 11 states. Among our customers are many of America’s best known companies, including Stop & Shop, Giant of Carlisle, Giant of Landover, Shaw’s, Great Atlantic & Pacific Tea Co. (A&P), Ralphs, Safeway and Target.

About Marathon Health

Marathon Health of Colchester, VT, offers a proven solution for helping employers reduce the total cost of healthcare. The Marathon Health approach integrates the best practices of onsite primary care, health assessment with risk identification, coaching and advocacy, and disease management for high cost chronic conditions. Marathon Health supports its unique model with an eHealth Portal delivering medical content, interactive diet and fitness tools, a personal health record, and an electronic medical record to manage care. For more information, please visit www.marathon-health.com.

UTICA, NY–(Marketwire – December 3, 2010) – CONMED Corporation (NASDAQ: CNMD), a medical technology company specializing in medical devices for surgical and patient monitoring markets, announced today that the U.S. Food and Drug Administration has given marketing clearance for the Company’s thermal energy based tissue fusion system for use in a wide range of surgical procedures. 

“We look forward to introducing our tissue sealing device, the Altrus® Thermal Tissue Fusion System, to the surgical community,” noted Mr. Joseph J. Corasanti, President and CEO of CONMED. “We believe the current marketplace for energy based instruments approximates $1.5 billion, and while our initial revenue goals for Altrus® in 2011 are modest at $5 – $10 million, we expect Altrus® to be a contributor to our long-term growth prospects.”

Over the last several years, surgeons have expanded the use of energy based instruments to reduce surgical times, improve patient outcomes and decrease procedure costs. Based on CONMED’s original research in the technology, and with the understanding of surgeon needs, CONMED has developed the Altrus® Thermal Tissue Fusion system to advance the performance of energy-based instrumentation. Utilizing thermal energy, the Altrus® System is a multi-functional surgical tool that seals, cuts, grasps, and dissects vessels up to 7mm in size utilizing a closed feedback loop between the energy source and the single-use handpiece to precisely control the desired effect on tissue. Its versatility reduces the need for multiple instruments and instrument changes.

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company’s products serve the clinical areas of sports medicine-arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. Surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology use the Company’s medical devices. Headquartered in Utica, New York, the Company’s 3,300 employees distribute its products worldwide from several manufacturing locations. 

Forward Looking Information

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; and/or (vii) the Company’s ability to devise and execute strategies to respond to market conditions.

PLEASANTON, CA–(Marketwire – December 3, 2010) – Callidus Software (NASDAQ: CALD)

WHO:

G. F. “Will” Williams, senior incentive compensation analyst, Philips Healthcare

WHAT:

Is your workforce delivering the results that you need? Are they truly aligned with your top-tier business objectives? Learn how best-in-class organizations outperform competitors by using Management-by-Objective (MBO) programs to drive business performance.

WHEN:

Thursday, December 9, 2010

11 a.m. Pacific / 1 p.m. Central / 2 p.m. Eastern Time

WHERE:

To register for the event and for additional information go to:
http://www2.callidussoftware.com/Q410-MBO-Webinar.html

If you cannot attend the live event, please register and we will send you the on-demand version when available.

In the webinar, you will learn:

• Best practices in developing and administering MBOs
• How to develop MBOs that motivate employees and drive them toward accomplishing top-tier corporate objectives
• How to enhance employee engagement
• How to overcome common challenges that can potentially hinder your success

About Royal Philips Electronics

Royal Philips Electronics of the Netherlands (NYSE: PHG) (AMS: PHI), which includes Philips Healthcare, is a diversified health and well-being company, focused on improving people’s lives through timely innovations. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of “sense and simplicity”. Headquartered in the Netherlands, Philips employs more than 116,000 employees in more than 60 countries worldwide. With sales of EUR 23 billion in 2009, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in flat TV, male shaving and grooming, portable entertainment and oral healthcare. News from Philips is located at www.philips.com/newscenter.

About Callidus Software®

Callidus Software (NASDAQ: CALD) is the market and technology leader in Sales Performance Management (SPM). Callidus customers gain a competitive advantage by maximizing sales cost efficiencies and driving improvements in sales effectiveness. Our award-winning Software-as-a-Service (SaaS) applications set the standard for performance management of a company’s sales force and channel partners. Over 2 million employees and channel partners have their performance managed by Callidus Software. For more information, please visit www.callidussoftware.com.

©1997-2010 Callidus Software Inc. All rights reserved. Callidus Software, the Callidus Software logo, and TrueComp Manager are trademarks, service marks, or registered trademarks of Callidus Software Inc. in the United States and other countries. All other brand, service or product names are trademarks or registered trademarks of their respective companies or owners.

Click here to see all recent news from this company